Surrozen's SZN-043 for Severe Alcohol-Associated Hepatitis Enters Phase 1b Clinical Trial
Tuesday, 4 June 2024, 09:48
Surrozen Initiates Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen has taken a pivotal step by commencing the dosing of the first patient in the Phase 1b Clinical Trial of SZN-043, targeted at Severe Alcohol-Associated Hepatitis. This milestone highlights the company's commitment to advancing medical research and development in critical health areas.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.